semaglutide tfa

Semaglutide TFA is a glucagon-like peptide-1 congener that induces weight loss, lowers blood glucose levels, and reduces cardiovascular risk in diabetic patients.Semaglutide TFA induces mild-to-moderate and transient gastrointestinal disturbances, and may be used in the study of type 2 diabetes and obesity.

Semaglutide-13C6,15N TFA, marked with 13C and 15N isotopes, is a form of Semaglutide TFA. This compound is a long-acting, selective, competitive, orally active GLP-1R agonist capable of crossing the blood-brain barrier. Upon GLP-1R activation, it stimulates insulin secretion, inhibits gastric emptying and appetite, and enhances autophagy while reducing oxidative stress and apoptosis (apoptosis). Additionally, it modulates mitochondrial function and lipid metabolism, such as reducing hepatic de novo lipogenesis. Semaglutide TFA exhibits activities including blood glucose reduction, weight loss, neuroprotection (such as improving motor function in Parkinson’s disease models and reducing α-synuclein aggregation), and amelioration of hepatic steatosis. It is useful for research into type 2 diabetes, obesity, Parkinson’s disease, metabolic-associated steatotic liver disease (MASLD), other neurodegenerative conditions, liver diseases, and cancer.